📰 BloombergBloombergCodex · 实盘不做把握 6/10
北京时间·🕒 发布 23:13:21时区推断·⟳ 抓取 23:24:26·⚡ 决策 07-23 23:25:48 +1m22s·95.9 天前
赛默飞二季度超预期并上调全年收入低端指引，仪器需求复苏带动股价盘中大涨
赛默飞二季度收入和 EPS 均超预期，Analytical Instruments 收入恢复增长，说明生物医药客户资本开支有改善。
📄 原文Bloomberg↗ 原文
Thermo Fisher Scientific Inc. raised its revenue forecast after stronger-than-expected spending by biotech and pharma c…
不做 赛默飞（TMO.US）
财报确为利好，但属于盘前预定披露，信号到达时 TMO.US 已一度上涨约 12%，全年指引上修量级有限，盘中追多没有足够 edge。
不做 丹纳赫（DHR.US）
仅为生命科学工具板块读出，不是丹纳赫自身公司级新催化，且同业已随 TMO 财报同步反应，不做二阶追多。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
消息传播链
- 公司按预定日程召开二季度业绩电话会，财报与全年预期更新属于盘前公开财报事件。
- 报道确认 TMO 二季度收入 119.9 亿美元、EPS 6.03 美元均高于预期，并带动生命科学工具板块反弹。市场反应:TMO.US 早盘涨逾 9%，同业 Danaher 也上涨。
- Bloomberg 报道仪器需求复苏和生物医药客户支出改善，称股价一度上涨约 12%。市场反应:TMO.US 已盘中大幅重定价。
关键理由
- 赛默飞二季度收入和 EPS 均超预期，Analytical Instruments 收入恢复增长，说明生物医药客户资本开支有改善。
- 全年收入指引仅把低端上调 1 亿美元至 474 亿美元，高端维持 481 亿美元，增量相对公司体量较小。
- 消息在盘前财报与 8:30 ET 电话会后已被市场迅速交易，Bloomberg 抓取时股价已一度上涨约 12%，追多边际收益不足。
主要风险
- 若生命科学工具板块复苏被后续同行财报连续确认，TMO.US 和 DHR.US 仍可能延续板块重估，但本条信号到达时已过第一反应窗口。
- 全年指引上修幅度偏温和，若后续订单恢复不持续，财报日大涨可能回吐。
反向证据
- 做多前查反向 · 来源 web · 日期 2026-07-23 · 影响 weakens
反向约束不是基本面利空，而是执行层面：信号到达时股价已盘中大涨，主要财报 surprise 已被交易。
检索:Thermo Fisher Q2 2026 earnings guidance stock jumped 12 percent 原文 ↗ - 做多前查反向 · 来源 web · 日期 2026-07-23 · 影响 weakens
全年收入指引只是把低端上调 1 亿美元，高端不变，相对 474亿-481 亿美元全年收入体量，新增量级有限。
检索:Thermo Fisher Q2 2026 revenue guidance raised low end 100 million 原文 ↗
原文全文
展开原文 · 1,358 字
Thermo Fisher Scientific Inc. raised its revenue forecast after stronger-than-expected spending by biotech and pharma customers and a rebound in laboratory instrument demand helped pushed second-quarter sales past expectations. Shares jumped.
The clearest signal of increased customer demand came from the company’s Analytical Instruments segment, which reached its fastest growth in two years. Segment revenue rose 6.9% to $1.8 billion after staying flat in the first quarter.
“Analytical Instruments was the star,” wrote RBC Capital Markets analyst Dan Leonard. “This is the signal the market has been waiting for.”
“We saw spending pick-up,” Chief Executive Officer Marc Casper said about the company’s biotech and pharma customers on the earnings call. “It’s good to see that’s translating into the revenue.”
The Massachusetts-based life sciences company now expects full-year adjusted earnings of $24.93 to $25.33 per share, above the $24.86 analyst estimate.
The company also raised the low end of its revenue forecast by $100 million to $47.4 billion and left the high end unchanged at $48.1 billion with organic growth seen at the top of its existing 3% to 4% range for the full year.
Sales and earnings for the three months through June 27 bested estimates.
Shares rose as much as 12% in New York trading, recouping all of this year’s losses.
The clearest signal of increased customer demand came from the company’s Analytical Instruments segment, which reached its fastest growth in two years. Segment revenue rose 6.9% to $1.8 billion after staying flat in the first quarter.
“Analytical Instruments was the star,” wrote RBC Capital Markets analyst Dan Leonard. “This is the signal the market has been waiting for.”
“We saw spending pick-up,” Chief Executive Officer Marc Casper said about the company’s biotech and pharma customers on the earnings call. “It’s good to see that’s translating into the revenue.”
The Massachusetts-based life sciences company now expects full-year adjusted earnings of $24.93 to $25.33 per share, above the $24.86 analyst estimate.
The company also raised the low end of its revenue forecast by $100 million to $47.4 billion and left the high end unchanged at $48.1 billion with organic growth seen at the top of its existing 3% to 4% range for the full year.
Sales and earnings for the three months through June 27 bested estimates.
Shares rose as much as 12% in New York trading, recouping all of this year’s losses.
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。